KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02162 KEYMED BIO-B

Closed 04-13 16:08:48

74.300

-0.700

-0.93%

High76.000	Low72.400	Vol1.90M
Open74.900	D1 Closing75.000	Amplitude4.80%
Mkt Cap22.22B	Tradable Cap22.22B	Total Shares299.00M
T/O141.14M	T/O Rate0.63%	Tradable Shares299.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"KEYMED BIO-B","latestPrice":74.3,"timestamp":1776067728003,"preClose":75,"halted":0,"volume":1896286,"delay":0,"changeRate":-0.00933333333333337,"floatShares":299000000,"shares":299000000,"eps":-2.1889405306352585,"marketStatus":"Closed","change":-0.7,"latestTime":"04-13 16:08:48","open":74.9,"high":76,"low":72.4,"amount":141143769,"amplitude":0.048,"askPrice":74.4,"askSize":4000,"bidPrice":74.3,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":-2.219883669026438,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776130200000},"marketStatusCode":5,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":75,"openAndCloseTimeList":[[1776043800000,1776052800000],[1776056400000,1776067200000]],"volumeRatio":0.357663,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162","defaultTab":"news","newsList":[{"id":"1118145069","title":"KEYMED BIO-B (02162) Rises Nearly 6% Again as CMG313 Sales Accelerate and Global Value Pathway Clarifies","url":"https://stock-news.laohu8.com/highlight/detail?id=1118145069","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118145069?lang=en_us&edition=fundamental","pubTime":"2026-04-02 14:36","pubTimestamp":1775111818,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B (02162) gained nearly 6% again, rising 5.97% to HK$71 by the time of writing, with a turnover of HK$415 million. On the news front, KEYMED BIO's 2025 results showed the company achieved...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1574","BK4588","BK1161","VXUS","BK1583","BK4585","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168735452","title":"KEYMED BIO-B Reports Unchanged Share Capital and Confirms Public Float Compliance for March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1168735452","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168735452?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:47","pubTimestamp":1775033238,"startTime":"0","endTime":"0","summary":"Keymed Biosciences Inc. (KEYMED BIO-B) has released its Monthly Return for Equity Issuer covering the period ended 31 March 2026, indicating a stable capital structure and adherence to Hong Kong...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623359243","title":"A Look At Keymed Biosciences (SEHK:2162) Valuation After Annual Results And Commercialization Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2623359243","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623359243?lang=en_us&edition=fundamental","pubTime":"2026-03-29 19:10","pubTimestamp":1774782626,"startTime":"0","endTime":"0","summary":"Why Keymed Biosciences just drew fresh attention\nKeymed Biosciences (SEHK:2162) has come into focus after releasing its 2025 annual results, with higher reported sales, a wider net loss in absolute terms, and a slightly smaller loss per share from continuing operations.\nSee our latest analysis for Keymed Biosciences.\nThe latest earnings release and wider shift toward commercialization appear to be feeding into stronger momentum, with a 1-day share price return of 5.03% and a 1-year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/a-look-at-keymed-biosciences-sehk2162-valuation-after-annual","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/a-look-at-keymed-biosciences-sehk2162-valuation-after-annual","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK1583","02162","BK4097","BK1161","BK1587","LU2065732104.USD","BK1574","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622880552","title":"Keymed Biosciences (SEHK:2162) Loss Narrowing In 1H 2025 Tests Premium Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2622880552","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622880552?lang=en_us&edition=fundamental","pubTime":"2026-03-28 03:14","pubTimestamp":1774638852,"startTime":"0","endTime":"0","summary":"Keymed Biosciences (SEHK:2162) has just posted FY 2025 first half revenue of C¥498.8 million with a basic EPS loss of C¥0.30 per share, while trailing twelve month figures show revenue of C¥716.3 million and a basic EPS loss of C¥1.91. Over recent reporting halves, the company has seen revenue move from C¥54.7 million in 1H 2024 to C¥373.4 million in 2H 2024 and then to C¥498.8 million in 1H 2025, alongside basic EPS losses of C¥1.29, C¥0.68 and C¥0.30 respectively. These figures place the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-loss-narrowing-in-1h-2025-tests","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-loss-narrowing-in-1h-2025-tests","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1587","02162","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622814770","title":"Keymed Biosciences' Loss Deepens in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2622814770","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622814770?lang=en_us&edition=fundamental","pubTime":"2026-03-27 12:38","pubTimestamp":1774586325,"startTime":"0","endTime":"0","summary":"Keymed Biosciences'  loss attributable to owners of the parent widened to 522.6 million yuan for 2025, from 515.2 million yuan a year earlier, according to a Thursday Hong Kong bourse filing.Shares of the drug company were up over 3% in Friday's late morning trade.Loss per share came in at 1.91 yuan, compared with 1.97 yuan a year earlier.Revenue rose 67% to 716.3 million yuan from 428.1 million yuan in 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1161","BK1587","BK1583","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622386599","title":"KeyMed Biosciences Announces 2025 Annual Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2622386599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622386599?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:54","pubTimestamp":1774533299,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA17XQ1J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02162","BK1574","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126545376","title":"KEYMED BIO-B Reports Widened Annual Loss Amid Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1126545376","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126545376?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:04","pubTimestamp":1774530287,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B (02162) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 716 million yuan, representing a 67% increase compared to the previous year....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1574","02162","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850069","title":"KeyMed Biosciences FY Revenue RMB 716.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850069","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850069?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:56","pubTimestamp":1774529779,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nPLX361527:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","BK1583","02162","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850061","title":"KeyMed Biosciences FY Net Income Attributable RMB -522.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850061?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:56","pubTimestamp":1774529779,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nPLX361527:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1574","BK1161","02162","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850032","title":"Keymed Biosciences FY2025; Kangyueda sales climb to CNY 315 million; revenue rises to CNY 716 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850032","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850032?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:56","pubTimestamp":1774529771,"startTime":"0","endTime":"0","summary":"Keymed said its IL-4Rα antibody product Kangyueda has received NMPA approvals covering three indications, supporting broader commercial reach in China.The company reported CNY 315.0 million in sales revenue from Kangyueda, indicating early-scale commercialization traction.Keymed said all approved Kangyueda indications and both vial and prefilled autoinjector formats were added to China’s national reimbursement drug list starting January 2026, a move that could expand patient access and influence adoption.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 26, 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL29GhMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1161","02162","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850740","title":"Keymed Biosciences FY2025 revenue rises 67% to RMB716 million; operating loss widens to RMB521 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850740","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850740?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:56","pubTimestamp":1774529767,"startTime":"0","endTime":"0","summary":"Keymed published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB716.3 million, up 67% year over year.Cost of sales was RMB88.0 million, while gross profit was RMB628.3 million, up 51%.Loss for the year was RMB522.6 million; adjusted loss for the year was RMB494.8 million.Cash and cash equivalents, time deposits, restricted cash and bank wealth management products totaled RMB2.0 billion, down 9%.Management said sales revenue from Kangyueda was about RMB315 million, up more than 8x, and attributed higher selling and distribution expenses of RMB322.0 million to increased Kangyueda sales.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLbR3PQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1583","02162","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156264604","title":"HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156264604","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156264604?lang=en_us&edition=fundamental","pubTime":"2026-03-24 09:46","pubTimestamp":1774316807,"startTime":"0","endTime":"0","summary":"HK Pharma Stocks Gained. Wuxi XDC up 8%; Wuxi AppTec up 7%; Transthera and HBM up 5%; Keymed Bio and Innocare up 4%; Wuxi Bio and Remegen up 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f33735d7734fa14183d39ed89303d740","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","02359","09995","09688","02137","09606","02269","03759","06606","06978","01672","02268","09966","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621367010","title":"BRIEF-Keymed Biosciences Disposes Equity Interest In- Ouro Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2621367010","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621367010?lang=en_us&edition=fundamental","pubTime":"2026-03-24 09:13","pubTimestamp":1774314827,"startTime":"0","endTime":"0","summary":"BRIEF-Keymed Biosciences Disposes Equity Interest In- Ouro MedicinesMarch 24  - Keymed Biosciences Inc 2162.HK:DISPOSAL OF EQUITY INTEREST IN- OURO MEDICINESTOTAL CONSIDERATION UP TO $2.175 BILLIONEXPECTED GAIN GROUP TO GENERATE FROM MERGER COMPRISING UPFRONT PAYMENT OF US$250 MILLION, OTHERSFurther company coverage: 2162.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40B118:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1583","02162","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151186146","title":"KEYMED BIO-B to Gain Up to $320 Million from Gilead's Acquisition of Stake-Held Ouro Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=1151186146","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151186146?lang=en_us&edition=fundamental","pubTime":"2026-03-24 06:52","pubTimestamp":1774306347,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B (02162) announced that the company, through its wholly-owned subsidiary, holds an approximately 15% minority equity interest in Ouro Medicines, which is recorded in the company's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","02162","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167023836","title":"Keymed Biosciences Sells 15% Stake in Ouro Medicines via US$2.18 Billion Gilead Merger, Eyes Up to US$320 Million Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=1167023836","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167023836?lang=en_us&edition=fundamental","pubTime":"2026-03-24 06:40","pubTimestamp":1774305633,"startTime":"0","endTime":"0","summary":"Keymed Biosciences Inc. (Keymed) announced that its wholly owned subsidiary, iBridge HK, will divest its entire 15 % interest in Ouro Medicines through a merger in which Gilead Sciences will acquire...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621080789","title":"KeyMed Biosciences Inc - Total Consideration up to $2.175 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621080789","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621080789?lang=en_us&edition=fundamental","pubTime":"2026-03-24 06:30","pubTimestamp":1774305035,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B118:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","02162","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621080787","title":"KeyMed Biosciences -  Expected Gain Group to Generate From Merger Comprising Upfront Payment of US$250 Mln, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2621080787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621080787?lang=en_us&edition=fundamental","pubTime":"2026-03-24 06:30","pubTimestamp":1774305035,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B118:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1161","BK1587","02162","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621080783","title":"KeyMed Biosciences Inc - Disposal of Equity Interest in- Ouro Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2621080783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621080783?lang=en_us&edition=fundamental","pubTime":"2026-03-24 06:30","pubTimestamp":1774305035,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B118:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1161","BK1587","02162","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620963044","title":"Assessing Keymed Biosciences (SEHK:2162) Valuation After CMG901 Phase III Milestone With AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=2620963044","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620963044?lang=en_us&edition=fundamental","pubTime":"2026-03-17 01:18","pubTimestamp":1773681497,"startTime":"0","endTime":"0","summary":"Keymed Biosciences (SEHK:2162) is back in focus after partner AstraZeneca began a Phase III trial of CMG901 in advanced gastric and related cancers, triggering a US$45 million milestone payment to the group.\nSee our latest analysis for Keymed Biosciences.\nThe CMG901 Phase III update comes after a strong 1 year total shareholder return of 50.97%. Shorter term share price momentum is steadier, with a 7 day share price return of 6.36% around the HK$54.35 level.\nIf you are looking for other...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/assessing-keymed-biosciences-sehk2162-valuation-after-cmg901","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/assessing-keymed-biosciences-sehk2162-valuation-after-cmg901","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4134","BK1574","BK1587","02162","III","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136749979","title":"Keymed Biosciences (02162) Schedules 26 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1136749979","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136749979?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:21","pubTimestamp":1773652899,"startTime":"0","endTime":"0","summary":"Keymed Biosciences Inc. (Stock Code: 02162) announced that its board of directors will convene on 26 March 2026. The agenda includes: • Reviewing and approving the consolidated financial results for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0512},{"period":"1month","weight":0.3812},{"period":"3month","weight":0.281},{"period":"6month","weight":0.0646},{"period":"1year","weight":0.8382},{"period":"ytd","weight":0.4032}],"compareEarnings":[{"period":"1week","weight":0.0309},{"period":"1month","weight":-0.0002},{"period":"3month","weight":-0.0129},{"period":"6month","weight":-0.0151},{"period":"1year","weight":0.252},{"period":"ytd","weight":0.0103}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.062159},{"month":2,"riseRate":0.6,"avgChangeRate":0.057033},{"month":3,"riseRate":0.4,"avgChangeRate":0.01927},{"month":4,"riseRate":1,"avgChangeRate":0.07745},{"month":5,"riseRate":0.25,"avgChangeRate":-0.097555},{"month":6,"riseRate":1,"avgChangeRate":0.124436},{"month":7,"riseRate":0.5,"avgChangeRate":0.132155},{"month":8,"riseRate":0.6,"avgChangeRate":0.038036},{"month":9,"riseRate":0.8,"avgChangeRate":0.042936},{"month":10,"riseRate":0.4,"avgChangeRate":0.003137},{"month":11,"riseRate":0.6,"avgChangeRate":0.04569},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144855}],"exchange":"SEHK","name":"KEYMED BIO-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"KEYMED BIO-B,02162,KEYMED BIO-B股票,KEYMED BIO-B股票老虎,KEYMED BIO-B股票老虎国际,KEYMED BIO-B行情,KEYMED BIO-B股票行情,KEYMED BIO-B股价,KEYMED BIO-B股市,KEYMED BIO-B股票价格,KEYMED BIO-B股票交易,KEYMED BIO-B股票购买,KEYMED BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}